CellCentric’s first-in-class p300/CBP inhibitor drug CCS1477; capsule production complete ready for the clinic
Production of CCS1477 in capsule form is now complete, ahead of forthcoming first-in-human clinical trials…
read more
Dr. Andrew Muir joined Midven in 2004. He is a Director of the Company and Fund Principal of the UK Innovation & Science Seed Fund and the Early Advantage fund.
After an initial scientific career at Zeneca he went on to roles in research and business development at the medical device company Biocompatibles and then Vice President of Technology for a US start-up in disinfection of medical equipment.
He started his career in VC with the £4m per annum Invention and Innovation seed capital fund at NESTA (the National Endowment for Science Technology and the Arts). He has a degree and a PhD in Chemistry from the University of Oxford.
Andrew combines a strong scientific and technical grounding with a real commercial pragmatism developed from his operational roles.
